GeoVax Vaccine Data Aligns With New IDSA Guidelines for Protecting Immunocompromised Patients
GeoVax's GEO-CM04S1 vaccine demonstrates robust T-cell responses and cross-variant durability in immunocompromised populations, addressing critical gaps identified in new IDSA guidelines that show current COVID-19 vaccines provide only moderate, short-lived protection for vulnerable patients.
The Infectious Diseases Society of America's new guidance on COVID-19 vaccination for immunocompromised patients aligns with recent clinical data from GeoVax Labs, highlighting the urgent need for alternative vaccine approaches for vulnerable populations. The IDSA guidance, issued October 17, 2025, concluded that existing COVID-19 vaccines provide only moderate and short-lived protection for immunocompromised patients, with effectiveness against hospitalization ranging from 33% to 56% and waning within two months.
GeoVax presented interim Phase 2 data for its GEO-CM04S1 vaccine at the World Vaccine Congress Europe 2025 in Amsterdam, demonstrating robust T-cell responses to both Spike and Nucleocapsid antigens that exceeded responses seen with mRNA boosters. The data showed broad, cross-variant immunity including activity against Omicron subvariants and a favorable safety profile with only mild-to-moderate adverse events and no vaccine-related serious adverse events reported.
David A. Dodd, Chairman & CEO of GeoVax, emphasized that immunocompromised Americans represent one in eight adults and include cancer patients, transplant recipients, people with autoimmune disease, and those living with HIV. "The new IDSA guidelines reinforce the urgent need for alternatives like GeoVax's GEO-CM04S1," Dodd stated. "Mainstream vaccine approaches, heavily centered on mRNA, continue to leave them without durable protection."
GEO-CM04S1 is a multi-antigen, Modified Vaccinia Ankara-based COVID-19 vaccine designed to elicit both antibody and T-cell immune responses. This dual-pathway activation is particularly important for patients who often fail to mount sufficient antibody responses with current mRNA vaccines. The vaccine's multi-antigen breadth, covering both Spike and Nucleocapsid proteins, is intended to provide broader immunologic coverage as the virus continues to evolve.
In patients with hematologic malignancies post-transplant or CAR-T therapy, breakthrough infections were mild-to-moderate, underscoring the vaccine's protective potential in highly vulnerable groups. Ongoing trials include Phase 2 studies as a primary vaccine for immunocompromised individuals and as a booster for patients with chronic lymphocytic leukemia. For more information about the company's clinical programs, visit https://www.geovax.com.
While mRNA vaccines were pivotal in the early pandemic response, their limitations in durability, breadth, and performance in immunocompromised populations highlight the risks of relying on a single platform. GEO-CM04S1 demonstrates how multi-antigen, T-cell-driven approaches can better protect high-risk populations and strengthen pandemic preparedness. "Protecting the over 40 million immunocompromised Americans is both a moral imperative and a national security necessity," Dodd added.